Copenhagen-based biotech company Freya Biosciences has secured a significant $38 million in Series A financing, led by Sofinnova Partners and OMX Ventures, alongside several other investors including The Export and Investment Fund of Denmark, Angelini Ventures, Mike Jafar Family Office, CE-Ventures, Corundum Systems Biology, and Indaco Venture Partners. The company focuses on advancing reproductive immunotherapies, particularly addressing infertility in women with dysbiotic vaginal microbiota during assisted reproductive technology (ART) procedures. This funding infusion will primarily be utilized to further the clinical development of their lead drug candidate, which is an investigational vaginal microbial immunotherapeutic, and to advance their multi-omics data science platform.
Freya Biosciences specializes in developing reproductive immunotherapies, focusing on women’s health issues. Their primary aim is to address conditions related to reproductive health, particularly infertility in women with dysbiotic vaginal microbiota undergoing assisted reproductive technology (ART) procedures. The company’s key focus lies in the advancement of a novel investigational vaginal microbial immunotherapeutic as their lead drug candidate. Additionally, they are dedicated to leveraging a multi-omics data science platform, incorporating deep microbiome sequencing and extensive immune biomarker profiling in human clinical samples. This approach enables them to gain comprehensive insights into reproductive health conditions and pave the way for innovative treatments targeting specific reproductive challenges faced by individuals, ultimately redefining fertility treatments for those previously underserved by existing options.
“We are very excited to announce Freya’s Series A fundraise, with the support of this dedicated team of investors,” said Colleen Acosta, CEO of Freya Biosciences. “Conditions that disproportionately and differently affect women have traditionally been underfunded in proportion to its burden on human health. Freya’s initial focus is on the millions of couples around the world that are struggling with infertility. This funding enables us to advance our groundbreaking immunotherapy platform targeting the vaginal microbiota and unlock its therapeutic potential in this area and beyond.”
Freya will advance the clinical development of its lead drug candidate, an investigational vaginal microbial immunotherapeutic, for the treatment of infertility in women with dysbiotic vaginal microbiota who are undergoing assisted reproductive technology (ART). The funding will also advance Freya’s multi-omics data science platform, which includes deep microbiome sequencing and vast multiplexed immune biomarker profiling in human clinical samples.
“Freya’s team of experts are uniquely positioned to shape a more comprehensive understanding of women’s health and disease to advance innovative solutions and novel treatment paradigms and we are confident in their success,” said Henrijette Richter, Managing Partner at Sofinnova Partners. “We look forward to supporting Freya as they continue to advance microbial immunotherapies to address reproductive health issues for which there are no treatments available.”
“OMX is proud to support Freya’s mission in women’s health and excited for Freya’s promising initial clinical results,” said Nick Haft, CEO of OMX Ventures. “We invest in trailblazing companies and Freya’s platform using microbial immunotherapies, supported by recent positive topline clinical results, has the potential to address a range of health conditions that uniquely affect women.”
Click to read more funding news.
